BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Friday, December 26, 2025
Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 25, 2008

View Archived Issues

BASF tenders offer to acquire Ciba

Read More

Results from PEARL trial with lasofoxifene presented at the ASBMR meeting

Read More

AC-100 promotes cartilage regeneration and repair in experimental models in goats

Read More

BTG makes recommended all share offer for Protherics

Read More

Transdel enrolls first patient in Ketotransdel phase III registration study

Read More

ReNeuron presents business update ahead of its 2008 Annual General Meeting

Read More

Array BioPharma reports development of soft calineurin inhibitors for atopic dermatitis

Read More

Maxygen and Astellas sign agreement for MAXY-4 in autoimmune diseases and transplant rejection

Read More

FDA requests 3-month extension on PDUFA deadline to review NovaDel's Zolpimist

Read More

Trillium secures new financing to fund development of TTI-1612

Read More

SIGA receives additional USD 20 million from the NIAID to develop antiviral ST-246

Read More

iBioPharma selects plant-made influenza vaccine as first clinical development candidate

Read More

p38alpha inhibitor developed at Abbott demonstrates beneficial activity in arthritis models

Read More

Allergy Therapeutics presents positive results from phase III Pollinex Quattro Ragweed study

Read More

Bristol-Myers Squibb to commence cash tender offer for ImClone Systems

Read More

CytRx completes Innovive acquisition and provides pipeline update

Read More

New pharmaceutical aids imparted by Emisphere

Read More

EMEA expands orphan medicinal product status for Neo-Bladder Augment

Read More

Recent patents describe novel agents for endocrine disorders

Read More

Novel asthma/COPD drug candidate AZD-1419 nominated for development

Read More

Cangene files MAA in Europe for HepaGam B solution for infusion or injection

Read More

Recent patents disclose novel antiinfective agents

Read More

Durect grants worldwide rights to Alpharma for Eladur pain patch

Read More

Genmab completes recruitment in phase II ofatumumab trial

Read More

Labopharm submits NDA to the FDA for DDS-04A to treat major depression

Read More

MethylGene and Celgene convert to milestone arrangement for MGCD-0103

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Dec. 24, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Dec. 24, 2025.
  • Illustration of magnifying glass looking at cancer in the brain

    Researchers discover how glioblastoma tumors dodge chemotherapy

    BioWorld MedTech
    Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
  • Left: Anthony Fauci. Right: Transmission electron micrograph of HIV-1 virus particles

    HIV research is close to a cure but far from ending the pandemic

    BioWorld
    Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
  • Illustration of tau accumulating in a neuron cell.

    ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug

    BioWorld
    ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing